© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 10th 2022
A review of the development of complement inhibitors and how the latest GATHER2 data support avacincaptad pegol for the treatment of geographic atrophy.
David R. Lally, MD, reviews the duration and patient demographic data of the investigative drug.
Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.
Local Approach Needed to Increase Hepatitis B Vaccinations in Indonesia
Study Finds Increased Risk of Psoriasis for Patients with Herpes Zoster
Both Ustekinumab, Vedolizumab Safe and Efficacious Treating Elderly Patients With IBD